Yimin Zhang

Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer

Di Wu, Chen Hu, Yong He, 2022, Thoracic cancer.

The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer

N. Yang, Yongchang Zhang, Yong He, 2022, Cancer medicine.

Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling

Y. Zhuang, Chen Hu, Xiaolin Tang, 2022, Communications Biology.

Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer

Yong He, Cheng Shen, Li Li, 2023, Cancer science.

Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer

Rui-guang Zhang, Yong He, Li Li, 2023, Targeted Oncology.

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC

Yong He, Yubo Wang, Caiyu Lin, 2023, iScience.

Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect

Caiyu Lin, Yuanyao Dou, Cong-hua Lu, 2024, Journal for ImmunoTherapy of Cancer.